Efficacy

Piqray (Alpelisib) Efficacy in Breast Cancer

Piqray (alpelisib) is a medication specifically approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. This indication is for use in combination with fulvestrant after disease progression following endocrine therapy. The efficacy of Piqray was primarily demonstrated in the SOLAR-1 clinical trial, which showed a significant improvement in progression-free survival (PFS) in patients with a PIK3CA mutation when compared to placebo plus fulvestrant. The trial found that patients treated with Piqray had a median PFS of 11.0 months versus 5.7 months for those on the placebo, indicating a substantial delay in disease progression for the Piqray group.

Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase) Efficacy in Breast Cancer

Phesgo is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with the enzyme hyaluronidase, and is used for the treatment of HER2-positive breast cancer. It is indicated for use in combination with chemotherapy for the treatment of early breast cancer at high risk of recurrence and for metastatic settings. The efficacy of Phesgo was established through studies that compared its use with pertuzumab and trastuzumab administered separately. The results demonstrated non-inferior levels of pertuzumab and trastuzumab in the blood, suggesting that Phesgo is as effective as the separate administrations of pertuzumab and trastuzumab when used alongside chemotherapy.

Both Piqray and Phesgo represent targeted therapies that have expanded the options for personalized treatment in breast cancer. Their development reflects the ongoing shift towards precision medicine, where treatments are tailored to the specific genetic and molecular characteristics of a patient's cancer. As such, they offer hope for improved outcomes in subsets of breast cancer patients with specific biomarkers, namely PIK3CA mutations for Piqray and HER2-positivity for Phesgo.

It is important to note that the efficacy of these treatments can vary based on individual patient factors, and they are not suitable for all breast cancer patients. The use of Piqray and Phesgo should be guided by a healthcare professional with consideration of the patient's specific type of breast cancer, genetic profile, and prior treatments. Patients should discuss the potential benefits and risks of these therapies with their oncologist to determine the most appropriate treatment plan for their condition.